These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 2159365)
21. Restored expression of transforming growth factor beta type II receptor in k-ras-transformed thyroid cells, TGF beta-resistant, reverts their malignant phenotype. Coppa A; Mincione G; Lazzereschi D; Ranieri A; Turco A; Lucignano B; Scarpa S; Ragano-Caracciolo M; Colletta G J Cell Physiol; 1997 Aug; 172(2):200-8. PubMed ID: 9258341 [TBL] [Abstract][Full Text] [Related]
22. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Fry AM; Chresta CM; Davies SM; Walker MC; Harris AL; Hartley JA; Masters JR; Hickson ID Cancer Res; 1991 Dec; 51(24):6592-5. PubMed ID: 1660343 [TBL] [Abstract][Full Text] [Related]
23. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Hsiang YH; Wu HY; Liu LF Cancer Res; 1988 Jun; 48(11):3230-5. PubMed ID: 2835157 [TBL] [Abstract][Full Text] [Related]
24. Quantitative adaptation of the bacteriophage P4 DNA unknotting assay for use in the biochemical and pharmacological characterization of topoisomerase II. Hofmann GA; Mirabelli CK; Drake FH Anticancer Drug Des; 1990 Aug; 5(3):273-82. PubMed ID: 2169250 [TBL] [Abstract][Full Text] [Related]
25. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249 [TBL] [Abstract][Full Text] [Related]
26. Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells. Markovits J; Pommier Y; Kerrigan D; Covey JM; Tilchen EJ; Kohn KW Cancer Res; 1987 Apr; 47(8):2050-5. PubMed ID: 3030540 [TBL] [Abstract][Full Text] [Related]
27. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Long BH; Wang L; Lorico A; Wang RC; Brattain MG; Casazza AM Cancer Res; 1991 Oct; 51(19):5275-83. PubMed ID: 1717144 [TBL] [Abstract][Full Text] [Related]
28. [Constitutive activity of MAP kinase cascades in REF cells transformed by E1A and cHa-ras oncogenes]. Svetlikova SB; Abramova MV; Kukushkin AN; Darieva ZA; Pospelova TV; Pospelov VA Tsitologiia; 2001; 43(10):961-8. PubMed ID: 11769129 [TBL] [Abstract][Full Text] [Related]
29. Resistance to apoptosis induced by alkylating agents in v-Ha-ras-transformed cells due to defect in p53 function. Kuo ML; Chou YW; Chau YP; Huang TS Mol Carcinog; 1997 Apr; 18(4):221-31. PubMed ID: 9142217 [TBL] [Abstract][Full Text] [Related]
31. Elevated topoisomerase II activity and altered chromatin in nitrogen mustard-resistant human cells. Tan KB; Mattern MR; Boyce RA; Hertzberg RP; Schein PS NCI Monogr; 1987; (4):95-8. PubMed ID: 2819739 [TBL] [Abstract][Full Text] [Related]
32. Topoisomerase II-mediated DNA damage of episomes in tumor-bearing mice. Cullinan EB; Gawron LS; Rustum YM; Beerman TA Cancer Res; 1990 Oct; 50(19):6154-7. PubMed ID: 2169334 [TBL] [Abstract][Full Text] [Related]
33. Transfection of EK-3, a subline of NIH 3T3, with the oncogene Ha-ras does not abolish its anchorage dependence. Katz E; Samid D Eur J Cell Biol; 1989 Aug; 49(2):221-4. PubMed ID: 2673787 [TBL] [Abstract][Full Text] [Related]
34. Role of proliferation in determining sensitivity to topoisomerase II-active chemotherapy agents. Sullivan DM; Chow KC; Glisson BS; Ross WE NCI Monogr; 1987; (4):73-8. PubMed ID: 2819735 [TBL] [Abstract][Full Text] [Related]
36. Evidence of DNA topoisomerase II-dependent mechanisms of multidrug resistance in P388 leukemia cells. De Isabella P; Capranico G; Binaschi M; Tinelli S; Zunino F Mol Pharmacol; 1990 Jan; 37(1):11-6. PubMed ID: 2153905 [TBL] [Abstract][Full Text] [Related]
37. Evidence for the participation of topoisomerases I and II in cadmium-induced metallothionein expression in Chinese hamster ovary cells. Mattern MR; Tan KB; Zimmerman JP; Mong SM; Bartus JO; Hofmann GA; Drake FH; Johnson RK; Crooke ST; Mirabelli CK Anticancer Drug Des; 1989 Aug; 4(2):107-24. PubMed ID: 2478139 [TBL] [Abstract][Full Text] [Related]
38. SCH 51344 inhibits ras transformation by a novel mechanism. Kumar CC; Prorock-Rogers C; Kelly J; Dong Z; Lin JJ; Armstrong L; Kung HF; Weber MJ; Afonso A Cancer Res; 1995 Nov; 55(21):5106-17. PubMed ID: 7585559 [TBL] [Abstract][Full Text] [Related]
39. A cisplatin-resistant murine leukemia cell line exhibits increased topoisomerase II activity. Barret JM; Calsou P; Larsen AK; Salles B Mol Pharmacol; 1994 Sep; 46(3):431-6. PubMed ID: 7935322 [TBL] [Abstract][Full Text] [Related]
40. Silencing of N-Ras gene expression using shRNA decreases transformation efficiency and tumor growth in transformed cells induced by anti-BPDE. Zhou L; Jiang Y; Tan A; Greenlee AR; Shen Y; Liu L; Yang Q Toxicol Sci; 2008 Oct; 105(2):286-94. PubMed ID: 18567617 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]